Pharmaceutical company Elan said today it plans to sell four pain products and related assets to aaiPharma for $100 million.
In 2002, Elan recorded net revenue of $59.8 million for the pain products and generated gross profit of $40.8 million, before sales and marketing costs and amortisation.
The carrying value of these pain products' intangible asset as at September 30th, 2003, amounted to about $68 million and Elan expects to record a pretax gain of approximately $30 million in respect of the disposal.
These products include the rights to Roxicodone (oxycodone hydrochloride) tablets and oral solution, Oramorph SR (morphine sulfate sustained-release) tablets, Roxanol (morphine sulfate) and Duraclon (clonidine hydrochloride injection).
The transaction is subject to regulatory approvals, third party consents and other customary conditions, and is expected to close during the fourth quarter of 2003.
AFP